Dupixent Shortage Update: What Patients Need to Know in 2026

Patients and caregivers have been searching for "Dupixent shortage 2026" in large numbers — and for good reason. Despite not being on the FDA's official shortage list, access to Dupixent is genuinely difficult for a large portion of the approximately 1 million-plus patients in the US who depend on it.

This post gives you the clearest, most current picture of Dupixent availability in 2026 — what's actually happening, why patients are struggling to access it, and what you can do.

Is There a Dupixent Shortage Right Now (2026)?

No — Dupixent is not on the FDA's official drug shortage list in 2026. Sanofi and Regeneron are actively manufacturing dupilumab. There is no manufacturing disruption, raw material shortage, or distribution breakdown that would constitute an FDA-defined drug shortage.

However, the access barriers surrounding Dupixent are significant enough that many patients experience what experts call a "practical access gap" — the drug is being made, but it's not reaching patients who need it on a timely basis.

Why Are Patients Struggling to Get Dupixent?

The difficulties patients face are not supply-based — they are access-based. The main drivers:

Specialty pharmacy requirements: Dupixent can only be dispensed by specialty pharmacies. It cannot be filled at a regular retail pharmacy, which limits the number of locations that can provide it.

Prior authorization delays: Nearly every insurance plan requires PA before covering Dupixent. The review process takes days to weeks and is frequently denied on the first attempt.

Step therapy requirements: Many plans require patients to try and fail on cheaper medications before approving Dupixent.

High cost: The 2026 list price is $4,193 per carton. Without insurance or assistance programs, this is unaffordable for most patients.

Formulary changes: Annual formulary updates can remove Dupixent from coverage or move it to a higher cost-sharing tier, disrupting patients who were previously covered.

What's Changed for Dupixent in 2025–2026?

There have been several important developments affecting Dupixent patients entering 2026:

9th FDA indication approved: In April 2026, Dupixent received FDA approval for chronic spontaneous urticaria (CSU) in children aged 2–11, adding to its list of indications and further expanding the patient population.

First biosimilar approved: The FDA approved a biosimilar to Dupixent, though it had not launched commercially as of early 2026. When biosimilars become available, they may expand access and reduce costs.

Medicare Part D cap: In 2026, Medicare Part D patients have a $2,100 annual out-of-pocket cap on prescription drugs. This is beneficial for Dupixent patients on Medicare.

Insurance formulary shifts: Some plans updated their formularies effective January 2026, altering tier placement and PA requirements. Patients should re-verify their coverage at the start of the year.

Are Any Dupixent Doses or Strengths Harder to Find Than Others?

In terms of physical supply, Dupixent comes in 200 mg and 300 mg prefilled pens and syringes. No specific strength or form has been reported in short supply in 2026. The availability challenges are uniform across doses and are access-related rather than supply-related.

What Can Patients Do Right Now?

If you're experiencing difficulty accessing Dupixent, take these steps:

Re-verify your insurance coverage — especially if your plan updated its formulary for 2026.

Contact DUPIXENT MyWay at 1-844-387-4936 — they can help with PA appeals, copay cards, and patient assistance.

Appeal any insurance denial — most are overturned with proper documentation.

Use medfinder to find specialty pharmacies near you that can fill your Dupixent prescription once your PA is approved.

The Outlook for Dupixent Availability in 2026

The manufacturing outlook for Dupixent in 2026 is stable. As biosimilars come to market — potentially beginning with commercial launches in 2026 or 2027 — competition may improve access and reduce costs. In the meantime, patients facing access hurdles should exhaust all available assistance programs before switching medications. For more information on your options if you cannot get Dupixent, see our post: Alternatives to Dupixent if you can't fill your prescription.